Survodutide: the complete guide
Survodutide is a once-weekly dual GLP-1 / glucagon receptor agonist under clinical development for obesity and metabolic dysfunction–associated steatohepatitis (MASH). Early trials show deep weight-loss effects comparable to the next-generation incretin class.
How Survodutide works
Survodutide activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and slows gastric emptying; the glucagon arm increases energy expenditure and supports hepatic lipid oxidation, which is why MASH is a primary indication.
Typical Survodutide dosage
Commonly reported research ranges: Trial titration: 0.6 → 2.4 → 3.6 → 4.8 mg weekly.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute Survodutide
A widely used reconstitution for a 10 mg vial is 2 ml of bacteriostatic water. With a typical 600 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 5 days (once-weekly dosing).
This half-life informs how often Survodutide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Reported side effects
- Nausea and GI effects during titration
- Injection-site reactions
- Potential transaminase elevations (monitored in MASH trials)
- Limited long-term data
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common Survodutide stacks
- Typically monotherapy
Storage and handling
Lyophilized: refrigerated. Reconstituted: refrigerated, use within 28 days.
FDA and regulatory status
Investigational. Not FDA approved. Phase III trials ongoing for obesity and MASH.
Survodutide clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- Survodutide clinical trial records — ClinicalTrials.gov
Track your Survodutide protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is Survodutide?
Survodutide is a once-weekly dual GLP-1 / glucagon receptor agonist under clinical development for obesity and metabolic dysfunction–associated steatohepatitis (MASH). Early trials show deep weight-loss effects comparable to the next-generation incretin class.
How does Survodutide work?
Survodutide activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and slows gastric emptying; the glucagon arm increases energy expenditure and supports hepatic lipid oxidation, which is why MASH is a primary indication.
What is a typical Survodutide dose?
Commonly reported ranges are Trial titration: 0.6 → 2.4 → 3.6 → 4.8 mg weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of Survodutide?
Approximately 5 days (once-weekly dosing). This influences how often it is administered.
How do you reconstitute Survodutide?
A common approach is to add 2 ml of bacteriostatic water to a 10 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of Survodutide?
Nausea and GI effects during titration; Injection-site reactions; Potential transaminase elevations (monitored in MASH trials); Limited long-term data.
Is Survodutide FDA approved?
Investigational. Not FDA approved. Phase III trials ongoing for obesity and MASH.
Are there clinical trials for Survodutide?
Registered or published clinical-trial sources for Survodutide are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- Survodutide literature (PubMed) — National Library of Medicine. Primary research on survodutide development and trials
- Survodutide clinical trial records — ClinicalTrials.gov. Phase II/III trials in obesity and MASH
- Le Roux et al. — Survodutide Phase II obesity results — PubMed. Key Phase II obesity trial publications
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.